Highlights: The therapeutic landscape for non-small cell lung cancer (NSCLC) is quickly evolving, and novel targeted medicines utilized in conjunction with companion molecular diagnostics are becoming increasingly biomarker-driven. 1 Newer next-generation sequencing (NGS) methods allow for a complete assessment by interrogating a comprehensive panel of clinically relevant genes, the entire genome, or the whole exome, depending on the design. 2 This article describes the utility and clinical applications of NGS in diagnosing NSCLC.
Next-generation sequencing in NSCLC NGS is a broad method for analyzing sequences of deoxyribonucleic acid (DNA) and gene expression (Ribonucleic acid species). The NGS technology was created to solve the limitations of Sanger sequencing, but it has evolved in many areas of genomic research, including DNA, RNA, micro-RNA (miRNA), Chromatin immunoprecipitation…
